BioSpace News Archive

AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS).

Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic therapeutic development company, today announced the topline results of the first in human Phase 2 clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.

Paratek Pharmaceuticals announced that on December 31, 2021, the Company granted stock options and restricted stock units to two new employees of the Company.

ERYTECH Pharma announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

Kiniksa Pharmaceuticals, Ltd. announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.

Terns Pharmaceuticals, Inc. announced that the Company’s management team will present at the following investor conferences in January:

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 5,600 shares of Karyopharm’s common stock to 2 newly-hired employees, with a grant date of December 31, 2021.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors, effective immediately.

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the completion of the U.S. Phase I trial of ASC43F, an in-house developed, first-in-class dual targeting fixed-dose combination (FDC) tablet for non-alcoholic steatohepatitis (NASH).